Todd B. Sherer, PhD

Affiliations: 
Michael J Fox Foundation 
Google:
"Todd Sherer"
Mean distance: 17.21 (cluster 32)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Espay AJ, Vizcarra JA, Marsili L, et al. (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337
Akil H, Balice-Gordon R, Cardozo DL, et al. (2016) Neuroscience Training for the 21st Century. Neuron. 90: 917-26
Dorsey ER, Wagner JD, Bull MT, et al. (2015) Feasibility of Virtual Research Visits in Fox Trial Finder. Journal of Parkinson's Disease. 5: 505-15
Weintraub D, Simuni T, Caspell-Garcia C, et al. (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 919-27
Fuji RN, Flagella M, Baca M, et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine. 7: 273ra15
Rocker C, Cappelletti L, Marshall C, et al. (2015) Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder. Journal of Parkinson's Disease. 5: 55-66
Choi DW, Armitage R, Brady LS, et al. (2014) Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs. Neuron. 84: 554-63
Jankovic J, Sherer T. (2014) The future of research in Parkinson disease Jama Neurology. 71: 1351-1352
Dave KD, De Silva S, Sheth NP, et al. (2014) Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiology of Disease. 70: 190-203
Ko WK, Pioli E, Li Q, et al. (2014) Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 772-9
See more...